Updates are available Correction dated 2023-08-21

Article History

Accepted: 5 June 2023

First Online: 13 July 2023

Change Date: 21 August 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41573-023-00790-7

Competing interests

: T.B. was speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN Pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Evelo, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, MSD, Medac, Micreos, Nektar, Novartis, Numab, OM-Pharma, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB and Union Therapeutics. He is the founder and chairman of the board of the non-profit biotech ‘Davos Biosciences’ within the International Kühne-Foundation.